Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Given

Pulmonary Disease Fort Walton Beach, FL Medical Doctor

NPI 1104898980 CMS profile 94962

322 Racetrack Rd Ne, Fort Walton Beach, FL 32547

Open in the dashboard

General payments

$8,903

330 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Given of Fort Walton Beach, FL is reported in the CMS Open Payments database as having received $8,903 across 330 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,381 100
2024 General $1,512 66
2023 General $1,333 39
2022 General $1,394 41
2021 General $990 29
2020 General $714 29
2019 General $579 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Given
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Michael Given were reported at $2,381. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Michael Given Pulmonary Disease median Middle half National median
2019 $579 $377 $109–$1,340 $163
2020 $714 $230 $56–$907 $114
2021 $990 $269 $68–$1,072 $132
2022 $1,394 $390 $100–$1,457 $149
2023 $1,333 $419 $114–$1,659 $160
2024 $1,512 $476 $123–$1,818 $164
2025 $2,381 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,426 66 payments
  2. GlaxoSmithKline, LLC. $1,981 74 payments
  3. Grifols USA, LLC $875 46 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $495 22 payments
  5. Insmed, Inc. $457 16 payments
  6. Regeneron Healthcare Solutions, Inc. $425 16 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $304 18 payments
  8. Amgen Inc. $266 4 payments
  9. Genzyme Corporation $218 13 payments
  10. Verona Pharma, Inc. $177 10 payments
  11. Other $1,277 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,613 326 payments
  2. Consulting Fee $230 3 payments
  3. Education $60 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,095 46 payments
  2. Prolastin-C Liquid $875 46 payments
  3. BREZTRI $796 17 payments
  4. NUCALA $515 22 payments
  5. OFEV $458 19 payments
  6. Arikayce $457 16 payments
  7. FARXIGA $402 9 payments
  8. TEZSPIRE $378 9 payments
  9. GLASSIA $336 20 payments
  10. DUPIXENT $292 10 payments
  11. Other $3,248 125 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,217

Median for Pulmonary Disease: 936

Drug cost

$725,133

Median for Pulmonary Disease: $487,987

Branded share of claims

68.4%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 358 $313,694
Ofev Nintedanib Esylate Brand 11 $143,277
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 131 $102,643
Dupixent Pen Dupilumab Brand 19 $101,745
Breo Ellipta Fluticasone/Vilanterol Brand 43 $21,918
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 28 $12,177
Neupro Rotigotine Brand 11 $9,326
Eliquis Apixaban Brand 13 $7,606
Albuterol Sulfate Hfa Albuterol Sulfate Brand 164 $6,412
Ventolin Hfa Albuterol Sulfate Brand 31 $1,856

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$64,957

Medicare's payments for the services billed

Medicare patients

344

Average age 76

Services billed

747

167 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
COPD 58%
Ischemic heart disease 41%
Diabetes 33%
Chronic kidney disease 33%
Heart failure 32%
Atrial fibrillation 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $181
$181 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $164
$164 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $135
$135 358 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $121
$121 131 —
AREXVY
  • GlaxoSmithKline, LLC. $121
$121 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

330 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record